JPRN-jRCT2080220290未知3 期
Add-on, open-label, phase III study of CS-866AZ
DAIICHISANKYO Co.,Ltd.0 个研究点开始时间: 2006年8月10日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Patient with essential hypertension not adequately controlled by CS-866 and CS-905 monotherapy, aged 20 years or older
排除标准
- 未提供
研究者
相似试验
未知
3 期
Open-label, phase III study of CS-866AZEssential hypertensionJPRN-jRCT2080220439DAIICHISANKYO Co.,Ltd.
已完成
3 期
AURA3JPRN-jRCT2080222601AstraZeneca
进行中（未招募）
1 期
AZD9291 versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancerocally Advanced or Metastatic Non-Small Cell Lung Cancer where Disease has Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and where Tumours harbour a T790M mutation within the Epidermal Growth Factor Receptor GeneMedDRA version: 19.0Level: PTClassification code 10029515Term: Non-small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-000594-39-GBAstraZeneca AB410
进行中（未招募）
1 期
AZD9291 versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancerocally Advanced or Metastatic Non-Small Cell Lung Cancer where Disease has Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and where Tumours harbour a T790M mutation within the Epidermal Growth Factor Receptor GeneMedDRA version: 20.0Level: PTClassification code 10029515Term: Non-small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-000594-39-SEAstraZeneca AB410
进行中（未招募）
1 期
AZD9291 versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung CancerEUCTR2014-000594-39-FRAstraZeneca AB610